RESUMEN
Background: The gap in the knowledge of interns between brand names, generic name and indication of a drug can lead to unwanted clinical consequences. This study was conducted to assess the knowledge of interns at a tertiary care hospital regarding the generic name and indications of the routinely prescribed brand names of drugs.Methods: In this study, interns were required to write whether they prescribed the brand names mentioned in the questionnaire in the preceding six months, their generic name and the indication for their use. Results were expressed using descriptive statistics.Results: All brands except Zovobact SB was prescribed by more than 50% of interns in the preceding six months. The generic equivalents were correctly identified by good percentage of interns for Hicet (100%), Asthalin (95%), Cifran (90%) but the percentage of correct answers was low for other brands. For combination brands, correct generic names of all components were identified by more than 50% of interns for oflox TZ (93%), Septid D (68%) and Losar H (68%). The percentage of correct response for the indication of the brands was satisfactory for Hicet (100%), Asthalin (98%), Cifran (98%), Zerodol P (100%), Cyclopam (100%), oflox TZ (100%), Losar H (98%), Septid D (98%) but was inadequate for Taxim O (48%), Betaloc (33%), Valium (23%), Diamox (0%), Quadriderm (31%) and Zovobact SB (31%).Conclusions: This study identified lacunas in the knowledge of interns regarding generic equivalents and indications of brand names. Strategies to overcome the problem should be devised to ensure patient safety.
RESUMEN
Background: Choice between LABAs and LTRAs as add on drugs to low dose ICS in persistent asthma remains unclear due to limited data on the comparative efficacy of these two groups of drugs. The aim of this study was to compare the effects of formoterol and montelukast on lung function, when added to low dose Budesonide in persistent asthma.Methods: This was an institution based randomized open label study. 72 asthmatics satisfying selection criteria of the study were randomized to receive either inhaled budesonide and formoterol (FB group) or inhaled budesonide and oral montelukast (MB group) for 12 weeks. PEF value at end point was primary efficacy measure. Secondary efficacy measures were PEF values measured at the end of 1, 4 and 8 weeks and the end point value of FEV1.Results: Both the groups showed significant improvement in the lung function tests. However inter-group comparison showed that PEF value at end point of FB group was significantly greater than that of MB group (81.94%vs 63.82%, p<0.05). Notable observation was that the superiority of the FB group with respect to PEF values was maintained from the first week itself. FB group also had significantly better results than MB group for FEV1 (67.88% vs 64.88%, p<0.05).Conclusions: In the present study, formoterol was found to be superior to montelukast in improving lung function when added to low dose budesonide in persistent asthma.